Research map: Effectiveness of RSV Prevention Strategies in US Infants: 2024–2025

Back to the article

Papers in this map

  1. The Burden of Respiratory Syncytial Virus Infection in Young Children · Caroline Breese Hall · 2009 · 2298 citations · Cited by this paper
  2. Comparative effectiveness of preventive strategies against medically-attended respiratory syncytial virus in U.S. infants during the first six months of life, 2023-2025 · Sara S. Kim · 2026 · Cites this paper
  3. Trends in Pediatric Hospitalizations Following Interfacility Transfer: 2009–2022 · 2026 · Related
  4. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants · Laura L. Hammitt · 2022 · 1053 citations · Cited by this paper
  5. Auricular Neurostimulation: A Novel Therapy for Abdominal Pain-Related Disorders of Gut-Brain Interaction · 2026 · Related
  6. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants · Beate Kampmann · 2023 · 1005 citations · Cited by this paper
  7. Telemedicine Use in Primary Care for Children: 2019–2024 · 2026 · Related
  8. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings · Mark G. Thompson · 2021 · 514 citations · Cited by this paper
  9. Hearing-Targeted Congenital Cytomegalovirus Screening: An 11-Year Experience · 2026 · Related
  10. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 · Jefferson M. Jones · 2023 · 368 citations · Cited by this paper
  11. Building the Foundations for Trustworthy AI in Pediatrics · 2026 · Related
  12. Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness · Sheena G. Sullivan · 2016 · 357 citations · Cited by this paper
  13. Blood Lead Testing Among Children Enrolled in Medicaid · 2026 · Related
  14. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 · Katherine E. Fleming-Dutra · 2023 · 311 citations · Cited by this paper
  15. Transplant Center Variability and Its Role in US Pediatric Liver Care Inequities · 2026 · Related
  16. Diagnostic Accuracy of Rapid Antigen Detection Tests for Respiratory Syncytial Virus Infection: Systematic Review and Meta-analysis · Caroline Chartrand · 2015 · 266 citations · Cited by this paper
  17. A Resource to Understand and Prevent Sudden Unexpected Infant Deaths · 2026 · Related
  18. Respiratory Syncytial Virus–Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis · John M. McLaughlin · 2020 · 126 citations · Cited by this paper
  19. Bias due to differential and non-differential disease- and exposure misclassification in studies of vaccine effectiveness · Tom De Smedt · 2018 · 69 citations · Cited by this paper
  20. Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal Peak · Natasha Halasa · 2023 · 59 citations · Cited by this paper
  21. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus · Hanmeng Xu · 2025 · 57 citations · Cited by this paper
  22. Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025 · Danielle Moulia · 2025 · 55 citations · Cited by this paper
  23. Effectiveness and Impact of Maternal RSV Immunization and Nirsevimab on Medically Attended RSV in US Children · Heidi L. Moline · 2025 · 39 citations · Cited by this paper
  24. Real-world effectiveness and safety of nirsevimab, RSV maternal vaccine and RSV vaccines for older adults: a living systematic review and meta-analysis · Bohee Lee · 2025 · 25 citations · Cited by this paper
  25. Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination — United States, October 2023–March 2024 · Ellen O'Neal Boundy · 2025 · 23 citations · Cited by this paper
  26. Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children — Yukon-Kuskokwim Delta Region, Alaska, October 2023–June 2024 · Brian Lefferts · 2024 · 21 citations · Cited by this paper
  27. Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization · Alice Shanklin · 2024 · 12 citations · Cited by this paper
  28. Impact of Nirsevimab on RSV and Non‐RSV Severe Respiratory Infections in Hospitalized Infants · María Luz García‐García · 2025 · 10 citations · Cited by this paper
  29. Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023–2024 · Laura L. Hammitt · 2025 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)